Results

1–10 of 86 results for wet AMD

The Role of Subretinal Surgery in the Treatment of Resistant Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Nabil M. Jabbour, MD, FACS
On Demand Cases, Courses, and Papers
2021
Higher-Order OCT Analysis From the HAWK Study: Longitudinal Dynamics in Fluid Burden, Outer Retinal Integrity, and Subretinal Hyperreflective Material
Justis P. Ehlers, MD, FASRS
On Demand Cases, Courses, and Papers
2021
A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD
Vrinda S. Hershberger, MD, PhD
On Demand Cases, Courses, and Papers
2021
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
2021
Subretinal Delivery of RGX-314 for Neovascular AMD: End of Study Phase I/IIa Results
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2021
Apples and Oranges: "Real-World" Outcomes Differ From Clinical Trial Outcomes Because "Real-World" Patients Differ From Clinical Trial Patients
Franco M. Recchia, MD
Annual Meeting Talks
2021
Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients With Wet AMD, DME, and BRVO
Suber S. Huang, MD, MBA, FASRS
Annual Meeting Talks
2021
Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy
Scott D Walter, MD, MSc
Annual Meeting Talks
2021
Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
W. Lloyd Clark, MD, FASRS
Updates from the Field
2022